PDS Biotechnology Corporation (PDSB)

3Q21 Contained Clinical Progress and New Product Licenses


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
November 11, 2021
Report ID: 24242
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


PDS Biotechnology Corporation
PDS Biotechnology Corporation
Healthcare
Biotechnology
Ticker
PDSB
Current Price
$4.62 -5.33%
Market Cap
$143.7M
Price Target
Refer to Report
Volume
1.0M
52wk Range
$3.8 - $10.27
Related Research Reports
3/4/2024

Clinical Trials Should Drive PDS In 2024
Clinical Trials Should Drive PDS In 2024 (PDSB)
11/15/2023

Clinical Milestones For 2024 Announced With 3Q23 Financial Results
Clinical Milestones For 2024 Announced With 3Q23 Financial Results (PDSB)
11/10/2023

Triple Therapy Data Shows Benefits That Far Exceed Published Studies
Triple Therapy Data Shows Benefits That Far Exceed Published Studies (PDSB)
10/12/2023

Data For PDS0301 Phase 1/2 To Show Immune Response and Safety Data
Data For PDS0301 Phase 1/2 To Show Immune Response and Safety Data (PDSB)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.